DeepMed Research

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Human interleukin-2

Generic Name: Human interleukin-2

Drug Type: Biotech

Unique Ingredient Identifier: FNO32LO217

Overview

Human interleukin-2 is under investigation in clinical trial NCT03475134 (TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in mMEL).

Background

Human interleukin-2 is under investigation in clinical trial NCT03475134 (TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in mMEL).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Efficacy and Safety of Low-dose IL-2 in SLE Patients With CMV Viremia

Phase 2

Not yet recruiting

Posted: 2025/05/14

Sponsor:Peking University Pe...

Phase I/II Clinical Trial f CD40L-augmented TIL for Patients With Advanced Melanoma

Phase 1

Not yet recruiting

Posted: 2025/05/07

Sponsor:H. Lee Moffitt Cance...

Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study

Phase 2

Not yet recruiting

Posted: 2025/03/19

Sponsor:The First Affiliated...

IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis

Phase 1

Suspended

Posted: 2024/11/07

Sponsor:Indapta Therapeutics...

TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas

Phase 1

Recruiting

Posted: 2024/10/15

Sponsor:Essen Biotech

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Amtagvi Shows Unprecedented 20% Five-Year Survival Rate in Advanced Melanoma Patients

2 days ago

Iovance Biotherapeutics has announced five-year results from the Phase 2 C-144-01 trial showing that one-time treatment with Amtagvi (lifileucel) achieved a 20% survival rate in advanced melanoma patients previously treated with checkpoint inhibitors.

Novel IL-2 Derivative Shows Complete Remission in Advanced Skin Cancer Patient After One Year

4 days ago

A 73-year-old patient with advanced cutaneous squamous cell carcinoma has remained cancer-free for over a year following treatment with WTX-124, a novel conditionally activated IL-2 pro-drug, in a clinical trial at HonorHealth Research Institute.

HCW Biologics' Novel Fusion Protein Shows Promise for Revolutionizing CAR-T Cell Production

12 days ago

HCW Biologics' proprietary fusion protein HCW9206 demonstrates superior efficacy in generating CAR-T cells with enhanced function and persistence compared to standard methods.

TILT Biotherapeutics Secures $25.6M Series B to Advance Novel Oncolytic Virus Therapy for Ovarian Cancer

12 days ago

TILT Biotherapeutics has raised $25.6 million in Series B funding to advance TILT-123, an oncolytic adenovirus engineered to enhance immune response against tumors, into Phase 2 trials for platinum-resistant ovarian cancer.

Artiva's AlloNK Shows Promising Durability in B-Cell Non-Hodgkin Lymphoma, Matching CAR-T Efficacy

a month ago

Artiva Biotherapeutics' AlloNK in combination with rituximab demonstrated a 64% complete response rate in heavily pretreated B-cell non-Hodgkin lymphoma patients, comparable to approved autologous CAR-T therapies.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy